Evidence map›Paper›PMID 31998283›Full record

ArticleFrontiers in immunology2019

Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice.

Lívia Pimentel de Sant'Ana, Dalila Juliana S Ribeiro, Aline Maria Araújo Martins, Fábio Neves Dos Santos, Rafael Corrêa, Raquel das Neves Almeida, Marcos Nogueira Eberlin, Corinne F Maurice, Kelly Grace Magalhães

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Research Progress of Pyroptosis in Fatty Liver Disease.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Drug Discovery in Liver Disease Using Kinome Profiling.International journal of molecular sciences · 2021
    Review
  15. Review
  16. Anti-Obesity Effect ofFrontiers in endocrinology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Lívia Pimentel de Sant'AnaLaboratory of Immunology and Inflammation, Department of Cell Biology, University of Brasilia, Brasília, Brazil.
Dalila Juliana S RibeiroLaboratory of Immunology and Inflammation, Department of Cell Biology, University of Brasilia, Brasília, Brazil.
Aline Maria Araújo MartinsCEMBIO-Centro de Metabolómica y Bioanálisis, Universidad San Pablo CEU, Madrid, Spain.
Fábio Neves Dos SantosThoMSon Mass Spectrometry Laboratory, Institute of Chemistry, University of Campinas-UNICAMP, São Paulo, Brazil.
Rafael CorrêaLaboratory of Immunology and Inflammation, Department of Cell Biology, University of Brasilia, Brasília, Brazil.
Raquel das Neves AlmeidaLaboratory of Immunology and Inflammation, Department of Cell Biology, University of Brasilia, Brasília, Brazil.
Marcos Nogueira EberlinDepartment of Chemistry, Mackenzie University, São Paulo, Brazil.
Corinne F MauriceDepartment of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
Kelly Grace MagalhãesLaboratory of Immunology and Inflammation, Department of Cell Biology, University of Brasilia, Brasília, Brazil.
Universidade de Brasília · BRMcGill University · CAUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade Presbiteriana Mackenzie · BRUniversidad San Pablo CEU · ES

Funding

CIHR PJT-149098
6 · The paper itself

Abstract

Obesity is a chronic disease with rising worldwide prevalence and largely associated with several other comorbidities, such as cancer, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. Hepatic steatosis, a hallmark of NAFLD, is strongly correlated with obesity and has been correlated with changes in the gut microbiota, which can promote its development through the production of short-chain fatty acids (SCFAs) that regulate insulin resistance, bile acid, choline metabolism, and inflammation. Recent studies have suggested a controversial role for the inflammasome/caspase-1 in the development of obesity and non-alcoholic steatohepatitis (NASH). Here, we evaluated the role of inflammasome NLRP3 and caspases 1/11 in the establishment of obesity and hepatic steatosis in diet-induced obese mice, correlating them with the global lipid profile of the liver and gut microbiota diversity. After feeding wild-type, caspases 1/11, and NLRP3 knockout mice with a standard fat diet (SFD) or a high-fat diet (HFD), we found that the caspases 1/11 knockout mice, but not NLRP3 knockout mice, were more susceptible to HFD-induced obesity, and developed enhanced hepatic steatosis even under SFD conditions. Lipidomics analysis of the liver, assessed by MALDI-MS analysis, revealed that the HFD triggered a significant change in global lipid profile in the liver of WT mice compared to those fed an SFD, and this profile was modified by the lack of caspases 1/11 and NLRP3. The absence of caspases 1/11 was also correlated with an increased presence of triacylglycerol in the liver. Gut microbial diversity analysis, using 16S rRNA gene sequencing, showed that there was also an increase of Proteobacteria and a higher Firmicutes/Bacteroidetes ratio in the gut of caspases 1/11 knockout mice fed an HFD. Overall, mice without caspases 1/11 harbored gut bacterial phyla involved with weight gain, obesity, and hepatic steatosis. Taken together, our data suggest an important role for caspases 1/11 in the lipid composition of the liver and in the modulation of the gut microbial community composition. Our results further suggest that HFD-induced obesity and the absence of caspases 1/11 may regulate both lipid metabolism and gut microbial diversity, and therefore may be associated with NAFLD and obesity.

Indexed as

Gastrointestinal MicrobiomeLipid MetabolismAnimalsBacteriaCaspase 1Caspases, InitiatorDiet, High-FatFatty Acids, VolatileFemaleHumansLiverMaleMiceMice, Inbred C57BLMice, KnockoutMice, ObeseCasp4 protein, mouseCaspase 1Caspases, InitiatorFatty Acids, VolatileNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousegut microbiotahigh-fat dietinflammasomeNAFLDobesity

Identifiers

PMID31998283
PMCPMC6962112
OpenAlexW3000454675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.